PRMT5 mutations are prevalent across a spectrum of cancer types, with a pronounced prevalence notably in CRC, pancreatic cancer, etc. This underscores their substantive role in the pathogenesis of these specific cancers, suggesting their potential as pivotal drivers [45]. This evidence concerns the gene PRMT5 and cancer.